Patient-reported outcomes in glomerular disease

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 1, 2017, Pages 140-148

  Selewski, David T ^a   Thompson, Aliza ^c   Kovacs, Sarrit ^c   Papadopoulos, Elektra J ^c   Carlozzi, Noelle E ^b   Trachtman, Howard ^d   Troost, Jonathan P ^a   Merkel, Peter A ^e   Gipson, Debbie S ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^d NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Disease Management; glomerulonephritis; Glomerulopathy; Humans; Kidney disease; Patient outcome assessment; Patient centered outcomes; Quality of life

Indexed keywords

ANCA ASSOCIATED VASCULITIS; ARTICLE; CLINICAL PRACTICE; EDEMA; GLOMERULOPATHY; HUMAN; KIDNEY POLYCYSTIC DISEASE; MEDICAL TERMINOLOGY; NEPHROTIC SYNDROME; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OUTCOME MEASURES IN RHEUMATOLOGY; PATIENT CARE; PATIENT REPORTED OUTCOME MEASUREMENT INFORMATION SYSTEM; PATIENT-REPORTED OUTCOME; PEDIATRIC QUALITY OF LIFE INVENTORY; PROTEINURIA; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; SCORING SYSTEM; SHORT FORM 36; CLINICAL TRIAL (TOPIC); COMPLICATION; GLOMERULUS; HEALTH STATUS; KIDNEY DISEASE; NOMENCLATURE;

ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; CLINICAL TRIALS AS TOPIC; HEALTH STATUS; HUMANS; KIDNEY DISEASES; KIDNEY GLOMERULUS; PATIENT REPORTED OUTCOME MEASURES; QUALITY OF LIFE; TERMINOLOGY AS TOPIC;

EID: 85019086157     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.13231215     Document Type: Article

References (49)

1. FDA: FDA Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdf. Accessed November 11, 2015
2. Perrone RD, Coons SJ, Cavanaugh K, Finkelstein F, Meyer KB: Patient-reported outcomes in clinical trials of CKD-related therapies: Report of a symposium sponsored by the national kidney foundation and the U.S. Food and Drug Administration. Am J Kidney Dis 62: 1046–1057, 2013
3. NCBI Bookshelf: BEST (Biomarkers, Endpoints, and Other Tools). Available at: http://www.ncbi.nlm.nih.gov/books/NBK338448/?report=reader. Accessed November 11, 2015
4. Peds QL: The PedsQL Measurement Model for the Pediatric Quality of Life Inventory. Available at: http://www.pedsql.org/. Accessed November 11, 2015
5. SF-36: 36-Item Short Form Survey from the RAND Medical Outcomes Study. Available at: http://www.rand.org/health/surveys_tools/mos/mos_core_36item.html. Accessed November 11, 2015
6. PROMIS: Dynamic Tools to Measure Health Outcomes from the Patient Perspective. Available at: http://www.nihpromis.org/?AspxAutoDetectCookieSupport=1. Accessed November 11, 2015
7. Rasch G: Probabilistic Models for Some Intelligence and Attainment Tests, Chicago, University of Chicago Press, 1960
8. Cappelleri JC, Jason Lundy J, Hays RD: Overview of classical test theory and item response theory for the quantitative assessment of items in developing patient-reported outcomes measures. Clin Ther 36: 648–662, 2014
9. Cronbach LJ, Meehl PE: Construct validity in psychological tests. Psychol Bull 52: 281–302, 1955
10. Revicki D, Hays RD, Cella D, Sloan J: Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes. J Clin Epidemiol 61: 102–109, 2008
11. Frost MH, Reeve BB, Liepa AM, Stauffer JW, Hays RD; Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group: What is sufficient evidence for the reliability and validity of patient-reported outcome measures? Value Health 10[Suppl 2]: S94–S105, 2007
12. NIH: PROMIS Instrument Development and Psychometric Evaluation Scientific Standard. Available at: http://www.nihpromis.org/Documents/PROMIS_Standards_050212.pdf?AspxAutoDetectCookieSupport=1. Accessed November 11, 2015
13. FDA: Code of Federal Regulations Title 21. Available at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr1/4314.126. Accessed April 6, 2016
14. Matza LS, Patrick DL, Riley AW, Alexander JJ, Rajmil L, Pleil AM, Bullinger M: Pediatric patient-reported outcome instruments for research to support medical product labeling: Report of the ISPOR PRO good research practices for the assessment of children and adolescents task force. Value Health 16: 461–479, 2013
15. Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, Suppiah R, Tomasson G, Luqmani RA: The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. J Rheumatol 38: 1480–1486, 2011
16. Tomasson G, Boers M, Walsh M, LaValley M, Cuthbertson D, Carette S, Davis JC, Hoffman GS, Khalidi NA, Langford CA, McAlear CA, McCune WJ, Monach PA, Seo P, Specks U, Spiera R, St Clair EW, Stone JH, Ytterberg SR, Merkel PA: Assessment of health-related quality of life as an outcome measure in granulomatosis with polyangiitis (Wegener’s). Arthritis Care Res (Hoboken) 64: 273–279, 2012
17. Walsh M, Mukhtyar C, Mahr A, Herlyn K, Luqmani R, Merkel PA, Jayne DR: Health-related quality of life in patients with newly diagnosed antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Care Res (Hoboken) 63: 1055–1061, 2011
18. Tomasson G, Davis JC, Hoffman GS, McCune WJ, Specks U, Spiera R, St Clair EW, Stone JH, Merkel PA: Brief report: The value of a patient global assessment of disease activity in granulomatosis with polyangiitis (Wegener’s). Arthritis Rheumatol 66: 428–432, 2014
19. Herlyn K, Hellmich B, Seo P, Merkel PA: Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. Arthritis Care Res (Hoboken) 62: 1639– 1645, 2010
20. Seo P, Jayne D, Luqmani R, Merkel PA: Assessment of damage in vasculitis: Expert ratings of damage. Rheumatology (Oxford) 48: 823–827, 2009
21. Milman N, Boonen A, Merkel PA, Tugwell P: Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health. Arthritis Care Res (Hoboken) 67: 255–263, 2015
22. Robson JC, Milman N, Tomasson G, Dawson J, Cronholm PF, Kellom K, Shea J, Ashdown S, Boers M, Boonen A, Casey GC, Farrar JT, Gebhart D, Krischer J, Lanier G, McAlear CA, Peck J, Sreih AG, Tugwell PS, Luqmani RA, Merkel PA: Exploration, development, and validation of patient-reported outcomes in antineutrophil cytoplasmic antibody-associated vasculitis using the OMERACT Process. J Rheumatol 42: 2204–2209, 2015
23. Geetha D, Specks U, Stone JH, Merkel PA, Seo P, Spiera R, Langford CA, Hoffman GS, Kallenberg CG, St Clair EW, Fessler BJ, Ding L, Tchao NK, Ikle D, Jepson B, Brunetta P, Fervenza FC; Rituximab for ANCA-Associated Vasculitis Immune Tolerance Network Research Group: Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement. J AmSoc Nephrol 26: 976–985, 2015
24. Wegener’s Granulomatosis Etanercept Trial (WGET) Research Group: Etanercept plus standard therapy for Wegener’s granulomatosis. N Engl J Med 352: 351–361, 2005
25. Gipson DS, Trachtman H, Kaskel FJ, Radeva MK, Gassman J, Greene TH, Moxey-Mims MM, Hogg RJ, Watkins SL, Fine RN, Middleton JP, Vehaskari VM, Hogan SL, Vento S, Flynn PA, Powell LM, McMahan JL, Siegel N, Friedman AL: Clinical trials treating focal segmental glomerulosclerosis should measure patient quality of life. Kidney Int 79: 678–685, 2011
26. Gipson DS, Selewski DT, Massengill SF, Wickman L, Messer KL, Herreshoff E, Bowers C, Ferris ME, Mahan JD, Greenbaum LA, MacHardy J, Kapur G, Chand DH, Goebel J, Barletta GM, Geary D, Kershaw DB, Pan CG, Gbadegesin R, Hidalgo G, Lane JC, Leiser JD, Plattner BW, Song PX, Thissen D, Liu Y, Gross HE, DeWalt DA: Gaining the PROMIS perspective from children with nephrotic syndrome: A Midwest pediatric nephrology consortium study. Health Qual Life Outcomes 11: 30, 2013
27. Selewski DT, Troost JP, Massengill SF, Gbadegesin RA, Greenbaum LA, Shatat IF, Cai Y, Kapur G, Hebert D, Somers MJ, Trachtman H, Pais P, Seifert ME, Goebel J, Sethna CB, Mahan JD, Gross HE, Herreshoff E, Liu Y, Song PX, Reeve BB, DeWalt DA, Gipson DS: The impact of disease duration on quality of life in children with nephrotic syndrome: A Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 30: 1467–1476, 2015
28. Libório AB, Santos JP, Minete NF, Diógenes CA, Soares AP, Queiroz AL, Barreto DM: Proteinuria is associated with quality of life and depression in adults with primary glomerulopathy and preserved renal function. PLoS One 7: e37763, 2012
29. A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients with Focal Segmental Glomerulosclerosis (FSGS). Available at: https://clinicaltrials.gov/ct2/show/NCT02000440. Accessed November 11, 2015
30. Gadegbeku CA, Gipson DS, Holzman LB, Ojo AO, Song PX, Barisoni L, Sampson MG, Kopp JB, Lemley KV, Nelson PJ, Lienczewski CC, Adler SG, Appel GB, Cattran DC, Choi MJ, Contreras G, Dell KM, Fervenza FC, Gibson KL, Greenbaum LA, Hernandez JD, Hewitt SM, Hingorani SR, Hladunewich M, Hogan MC, Hogan SL, Kaskel FJ, Lieske JC, Meyers KE, Nachman PH, Nast CC, Neu AM, Reich HN, Sedor JR, Sethna CB, Trachtman H, Tuttle KR, Zhdanova O, Zilleruelo GE, Kretzler M: Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney Int 83: 749–756, 2013
31. CureGN: Cure Glomerulonephroapthy Network. Available at: https://curegn.org/. Accessed November 11, 2015
32. Vodicka E, Kim K, Devine EB, Gnanasakthy A, Scoggins JF, Patrick DL: Inclusion of patient-reported outcome measures in registered clinical trials: Evidence from ClinicalTrials.gov (2007-2013). Contemp Clin Trials 43: 1–9, 2015
33. Finkelstein FO, Wuerth D, Finkelstein SH: Health related quality of life and the CKD patient: Challenges for the nephrology community. Kidney Int 76: 946–952, 2009
34. DeWitt EM, Stucky BD, Thissen D, Irwin DE, Langer M, Varni JW, Lai JS, Yeatts KB, Dewalt DA: Construction of the eight-item patient-reported outcomes measurement information system pediatric physical function scales: Built using item response theory. J Clin Epidemiol 64: 794–804, 2011
35. Thissen D, Liu Y, Magnus B, Quinn H, Gipson DS, Dampier C, Huang IC, Hinds PS, Selewski DT, Reeve BB, Gross HE, DeWalt DA: Estimating minimally important difference (MID) in PROMIS pediatric measures using the scale-judgment method. Qual Life Res 25: 13–23, 2016
36. Soni RK, Weisbord SD, Unruh ML: Health-related quality of life outcomes in chronic kidney disease. Curr Opin Nephrol Hypertens 19: 153–159, 2010
37. Leaf DE, Goldfarb DS: Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia. Kidney Int 75: 15–24, 2009
38. Ouzouni S, Kouidi E, Sioulis A, Grekas D, Deligiannis A: Effects of intradialytic exercise training on health-related quality of life indices in haemodialysis patients. Clin Rehabil 23: 53–63, 2009
39. Jhamb M, Cavanaugh KL, Bian A, Chen G, Ikizler TA, Unruh ML, Abdel-Kader K: Disparities in electronic health record patient portal use in nephrology clinics. Clin J Am Soc Nephrol 10: 2013–2022, 2015
40. Collister D, Komenda P, Hiebert B, Gunasekara R, Xu Y, Eng F, Lerner B, Macdonald K, Rigatto C, Tangri N: The effect of erythropoietin-stimulating agents on health-related quality of life in anemia of chronic kidney disease: A systematic review and meta-analysis. Ann Intern Med 164: 472–478, 2016
41. Farag YM, Keithi-Reddy SR, Mittal BV, Surana SP, Addabbo F, Goligorsky MS, Singh AK: Anemia, inflammation and health-related quality of life in chronic kidney disease patients. Clin Nephrol 75: 524–533, 2011
42. Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae SC, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V: The frequency and outcome of lupus nephritis: Results from an international inception cohort study. Rheumatology (Oxford) 55: 252–262, 2016
43. Miskulin DC, Abebe KZ, Chapman AB, Perrone RD, Steinman TI, Torres VE, Bae KT, Braun W, Winklhofer FT, Hogan MC, Rahbari-Oskoui F, Moore CG, Flessner MF, Schrier RW; HALT-PKD Study: Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: A cross-sectional study. Am J Kidney Dis 63: 214–226, 2014
44. Dobbels F, Wong S, Min Y, Sam J, Kalsekar A: Beneficial effect of belatacept on health-related quality of life and perceived side effects: Results from the BENEFIT and BENEFIT-EXT trials. Transplantation 98: 960–968, 2014
45. Lash JP, Wang X, Greene T, Gadegbeku CA, Hall Y, Jones K, Kusek JW, Sika M, Unruh M; African American Study of Kidney Disease and Hypertension Trial Study Group: Quality of life in the African American Study of Kidney Disease and Hypertension: Effects of blood pressure management. Am J Kidney Dis 47: 956–964, 2006
46. Wong C, Gerson A, Hooper SR, Matheson M, Lande M, Kupferman J, Furth S, Warady B, Flynn J; Chronic Kidney Disease in Children (CKiD) Study: Effect of elevated blood pressure on quality of life in children with chronic kidney disease [published online ahead of print February 8, 2016]. Pediatr Nephrol
47. Al-Uzri A, Matheson M, Gipson DS, Mendley SR, Hooper SR, Yadin O, Rozansky DJ, Moxey-Mims M, Furth SL, Warady BA, Gerson AC; Chronic Kidney Disease in Children Study Group: The impact of short stature on health-related quality of life in children with chronic kidney disease. J Pediatr 163: 736–741.e1, 2013
48. Gerson AC, Wentz A, Abraham AG, Mendley SR, Hooper SR, Butler RW, Gipson DS, Lande MB, Shinnar S, Moxey-Mims MM, Warady BA, Furth SL: Health-related quality of life of children with mild to moderate chronic kidney disease. Pediatrics 125: e349–e357, 2010
49. Selewski DT, Massengill SF, Troost JP, Wickman L, Messer KL, Herreshoff E, Bowers C, Ferris ME, Mahan JD, Greenbaum LA, MacHardy J, Kapur G, Chand DH, Goebel J, Barletta GM, Geary D, Kershaw DB, Pan CG, Gbadegesin R, Hidalgo G, Lane JC, Leiser JD, Song PX, Thissen D, Liu Y, Gross HE, DeWalt DA, Gipson DS: Gaining the Patient Reported Outcomes Measurement Information System (PROMIS) perspective in chronic kidney disease: A Midwest Pediatric Nephrology Consortium study. Pediatr Nephrol 29: 2347–2356, 2014